Quick Answer
RHYTHM PHARMACEUTICALS, INC. reported Diluted EPS of $3.11 per share (loss) for fiscal year 2025.
RHYTHM PHARMACEUTICALS, INC. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$3.11 | +28.3% |
| 2024 | -$4.34 | -35.6% |
| 2023 | -$3.20 | +7.8% |
| 2022 | -$3.47 | -147.9% |
| 2021 | -$1.40 | +53.9% |
| 2020 | -$3.04 | +21.2% |
| 2019 | -$3.86 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.82 | -12.3% | -9.3% |
| June 30, 2025 | -$0.75 | -36.4% | +7.4% |
| March 31, 2025 | -$0.81 | +65.5% | -11.0% |
| September 30, 2024 | -$0.73 | +3.9% | -32.7% |
| June 30, 2024 | -$0.55 | +32.9% | +76.6% |
| March 31, 2024 | -$2.35 | -155.4% | -209.2% |
| September 30, 2023 | -$0.76 | +3.8% | +7.3% |
| June 30, 2023 | -$0.82 | +7.9% | +10.9% |
- RHYTHM PHARMACEUTICALS, INC. showed an increase of +28.3% in Diluted EPS compared to the prior fiscal year.
- Over the 2019–2025 period, RHYTHM PHARMACEUTICALS, INC.’s diluted eps has grown by 19.4% (from $3.86 per share (loss) to $3.11 per share (loss)).
- The most recent figure is from RHYTHM PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: